Whole-exome sequencing identifies mutated PCK2 and HUWE1 associated with carcinoma cell proliferation in a hepatocellular carcinoma patient

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 847-851

  Liu, Yan Xuan ^a   Zhang, Shu Fang ^b   Ji, Ying Hua ^a   Guo, Sheng Ju ^a   Wang, Geng Fu ^a   Zhang, Guang Wen ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY   (China)

^b HAIKOU PEOPLE S HOSPITAL   (China)

Author keywords

Exome sequencing; Hepatocellular carcinoma; Somatic mutation

Indexed keywords

CDH12 PROTEIN; DNA; HUWE1 PROTEIN; OR1L3 PROTEIN; PCK2 PROTEIN; PHF16 PROTEIN; PPCS PROTEIN; PROTEIN; SPATA21 PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BIOINFORMATICS; CANCER PATIENT; CANCER TISSUE; CARCINOMA CELL; CASE REPORT; CELL PROLIFERATION; DNA SEQUENCE; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

EID: 84864829326     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.825     Document Type: Article

References (25)

1. Motola-Kuba D, Zamora-Valdés D, Uribe M and Méndez-Sánchez N: Hepatocellular carcinoma. An overview. Ann Hepatol 5: 16-24, 2006.
2. Srivatanakul P, Sriplung H and Deerasamee S: Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 5: 118-125, 2004.
3. McGlynn KA and London WT: Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19: 3-23, 2005.
4. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 40 (Suppl 1): S5-S10, 2006.
5. Teo EK and Fock KM: Hepatocellular carcinoma: an Asian perspective. Dig Dis 19: 263-268, 2001.
6. Li H and Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595, 2010.
7. Li H, Handsaker B, Wysoker A, et al; 1000 Genome Project Data Processing Subgroup: The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079, 2009.
8. Koboldt DC, Zhang Q, Larson DE, et al: VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22: 568-576, 2012.
9. Robinson JT, Thorvaldsdóttir H, Winckler W, et al: Integrative genomics viewer. Nat Biotechnol 29: 24-26, 2011.
10. Pollard KS, Hubisz MJ, Rosenbloom KR and Siepel A: Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res 20: 110-121, 2010.
11. Schwarz JM, Rödelsperger C, Schuelke M and Seelow D: MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 7: 575-576, 2010.
12. Cole C, Barber JD and Barton GJ: The Jpred 3 secondary structure prediction server. Nucleic Acids Res 36: W197-W201, 2008.
13. Llovet JM, Di Bisceglie AM, Bruix J, et al; Panel of Experts in HCC-Design Clinical Trials: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711, 2008.
14. Edamoto Y, Hara A, Biernat W, et al: Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 106: 334-341, 2003.
15. Hainaut P and Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137, 2000.
16. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928, 2008.
17. Sachdev D and Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6: 1-12, 2007.
18. Laurent-Puig P and Zucman-Rossi J: Genetics of hepatocellular tumors. Oncogene 25: 3778-3786, 2006.
19. Tang SH, Yang DH, Huang W, Zhou HK, Lu XH and Ye G: Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res 12: 4171-4177, 2006.
20. De Souza AT, Hankins GR, Washington MK, Orton TC and Jirtle RL: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11: 447-449, 1995.
21. Hanafusa T, Yumoto Y, Nouso K, et al: Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176: 149-158, 2002.
22. Tovar V, Alsinet C, Villanueva A, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52: 550-559, 2010.
23. Kim SO, Park JG and Lee YI: Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 56: 3831-3836, 1996.
24. Hill MR and McCallum RE: Identification of tumor necrosis factor as a transcriptional regulator of the phosphoenolpyruvate carboxykinase gene following endotoxin treatment of mice. Infect Immun 60: 4040-4050, 1992.
25. Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27: 55-76, 2007.